By Marie Rosenthal, MS
The FDA approved the chikungunya vaccine, recombinant vaccine for injection (Vimkunya, Bavarian Nordic), the first virus-like particle (VLP) single-dose vaccine in the United States for people 12 years of age and older.
The FDA approved Vimkunya under a Priority Review, based on results from two phase 3 clinical trials that enrolled 3,671 healthy people 12 years of age and older. The adult/adolescent trial (EBSI-CV-317-004) included 3,258 participants, and the older adult